Tags

Type your tag names separated by a space and hit enter

Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Abstract

The authors conducted a nested case-control study of serum steroid concentrations and risk of benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH over 7 years (n = 708) was defined as receipt of treatment, a report of 2 International Prostate Symptom Score (IPSS) values greater than 14, or 2 increases of 5 or more from baseline IPSS values with at least 1 value greater than or equal to 12. Controls (n = 709) were selected from men who reported no BPH treatment or any IPSS greater than 7. Baseline serum was analyzed for testosterone, estradiol, estrone, 5alpha-androstane-3alpha, 17beta-diol-glucuronide, and sex hormone-binding globulin. Covariate-adjusted odds ratios contrasting the highest quartiles with the lowest quartiles of testosterone, estradiol, and testosterone:17beta-diol-glucuronide ratio were 0.64 (95% confidence interval (CI): 0.43, 0.95; P(trend) = 0.04), 0.72 (95% CI: 0.53, 0.98; P(trend) = 0.09), and 0.64 (95% CI: 0.46, 0.89; P(trend) = 0.004), respectively. Findings did not differ by age, body mass index, time to BPH endpoint, or type of BPH endpoint. High testosterone levels, estradiol levels, and testosterone:17beta-diol-glucuronide ratio are associated with reduced BPH risk, which may reflect decreased activity of 5-alpha-reductase. Genetic or environmental factors that affect the activity of 5-alpha-reductase may be important in the development of symptomatic BPH.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4-B402, PO Box 19024, Seattle, WA 98109-1024, USA. akristal@fhcrc.org

    , , , , , , ,

    Source

    American journal of epidemiology 168:12 2008 Dec 15 pg 1416-24

    MeSH

    Aged
    Finasteride
    Follow-Up Studies
    Gonadal Steroid Hormones
    Humans
    Incidence
    Male
    Middle Aged
    Prevalence
    Prognosis
    Prostatic Hyperplasia
    Prostatic Neoplasms
    Retrospective Studies
    Sex Hormone-Binding Globulin
    Surveys and Questionnaires
    Time Factors
    United States

    Pub Type(s)

    Comparative Study
    Journal Article
    Randomized Controlled Trial
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    18945688

    Citation

    Kristal, Alan R., et al. "Serum Steroid and Sex Hormone-binding Globulin Concentrations and the Risk of Incident Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial." American Journal of Epidemiology, vol. 168, no. 12, 2008, pp. 1416-24.
    Kristal AR, Schenk JM, Song Y, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;168(12):1416-24.
    Kristal, A. R., Schenk, J. M., Song, Y., Arnold, K. B., Neuhouser, M. L., Goodman, P. J., ... Thompson, I. M. (2008). Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology, 168(12), pp. 1416-24. doi:10.1093/aje/kwn272.
    Kristal AR, et al. Serum Steroid and Sex Hormone-binding Globulin Concentrations and the Risk of Incident Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008 Dec 15;168(12):1416-24. PubMed PMID: 18945688.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. AU - Kristal,Alan R, AU - Schenk,Jeannette M, AU - Song,YoonJu, AU - Arnold,Kathryn B, AU - Neuhouser,Marian L, AU - Goodman,Phyllis J, AU - Lin,Daniel W, AU - Stanczyk,Frank Z, AU - Thompson,Ian M, Y1 - 2008/10/21/ PY - 2008/10/24/pubmed PY - 2008/12/31/medline PY - 2008/10/24/entrez SP - 1416 EP - 24 JF - American journal of epidemiology JO - Am. J. Epidemiol. VL - 168 IS - 12 N2 - The authors conducted a nested case-control study of serum steroid concentrations and risk of benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH over 7 years (n = 708) was defined as receipt of treatment, a report of 2 International Prostate Symptom Score (IPSS) values greater than 14, or 2 increases of 5 or more from baseline IPSS values with at least 1 value greater than or equal to 12. Controls (n = 709) were selected from men who reported no BPH treatment or any IPSS greater than 7. Baseline serum was analyzed for testosterone, estradiol, estrone, 5alpha-androstane-3alpha, 17beta-diol-glucuronide, and sex hormone-binding globulin. Covariate-adjusted odds ratios contrasting the highest quartiles with the lowest quartiles of testosterone, estradiol, and testosterone:17beta-diol-glucuronide ratio were 0.64 (95% confidence interval (CI): 0.43, 0.95; P(trend) = 0.04), 0.72 (95% CI: 0.53, 0.98; P(trend) = 0.09), and 0.64 (95% CI: 0.46, 0.89; P(trend) = 0.004), respectively. Findings did not differ by age, body mass index, time to BPH endpoint, or type of BPH endpoint. High testosterone levels, estradiol levels, and testosterone:17beta-diol-glucuronide ratio are associated with reduced BPH risk, which may reflect decreased activity of 5-alpha-reductase. Genetic or environmental factors that affect the activity of 5-alpha-reductase may be important in the development of symptomatic BPH. SN - 1476-6256 UR - https://www.unboundmedicine.com/medline/citation/18945688/Serum_steroid_and_sex_hormone_binding_globulin_concentrations_and_the_risk_of_incident_benign_prostatic_hyperplasia:_results_from_the_prostate_cancer_prevention_trial_ L2 - https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwn272 DB - PRIME DP - Unbound Medicine ER -